Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26814
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChandrashekar, Mohit-
dc.contributor.authorPhilip, Stuart-
dc.contributor.authorNesbitt, Alexander-
dc.contributor.authorJoshi, Andre-
dc.contributor.authorPerera, Marlon-
dc.date2021-06-22-
dc.date.accessioned2021-06-28T06:12:10Z-
dc.date.available2021-06-28T06:12:10Z-
dc.date.issued2021-06-22-
dc.identifier.citationInternational Journal of Urology 2021; online first: 22 Juneen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26814-
dc.description.abstractSodium glucose-linked transport protein 2 inhibitors are relatively novel drugs, used for the treatment of type 2 diabetes mellitus. Their use since Pharmaceutical Benefits Scheme approval in Australia has increased drastically, possibly due to the low risk of hypoglycemic events and their advertised cardiovascular mortality benefits. However, as with any novel drug, adverse effects regarding their use require medical practitioner awareness for optimal patient outcomes. This paper aims to cover the major urological implications, including those pertinent perioperatively, that concern this class of drugs. There is a clear risk of developing genital mycotic infections with the use of sodium glucose-linked transport protein 2 inhibitors, including serious infections such as Fournier's gangrene. Evidence for developing urinary tract infections has been mixed. Sodium glucose-linked transport protein 2 inhibitor-induced lower urinary tract symptoms may have impacts on quality of life via pollakiuria and nocturia, of which there are increased reports. Perioperative use increases the risk of euglycemic diabetic ketoacidosis. It is recommended that sodium glucose-linked transport protein 2 inhibitors be ceased perioperatively.en
dc.language.isoeng
dc.subjectdiabetic ketoacidosisen
dc.subjecthypoglycemic agentsen
dc.subjectlower urinary tract symptomsen
dc.subjecturinary bladder overactiveen
dc.subjecturinary tract infectionsen
dc.titleSodium glucose-linked transport protein 2 inhibitors: An overview of genitourinary and perioperative implications.en
dc.typeJournal Articleen
dc.identifier.journaltitleInternational Journal of Urologyen
dc.identifier.affiliationDepartment of Urology, Western Health, The University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationSchool of Medicine, Griffith University, Gold Coast, Queensland, Australiaen
dc.identifier.affiliationSurgery (University of Melbourne)en
dc.identifier.affiliationDepartment of Urology, Mater Hospital, Brisbane, Queensland, Australiaen
dc.identifier.affiliationFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australiaen
dc.identifier.doi10.1111/iju.14624en
dc.type.contentTexten
dc.identifier.pubmedid34155680
local.name.researcherPerera, Marlon
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.cerifentitytypePublications-
crisitem.author.deptSurgery-
crisitem.author.deptUrology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Dec 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.